• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / World News / Australasia / Australia / HPV Vaccination Programs: PhD Candidate Seeks Answers From Australian Health Authorities

HPV Vaccination Programs: PhD Candidate Seeks Answers From Australian Health Authorities

July 22, 2012 By Norma Leave a Comment

[SaneVax: PhD candidate Judy Wilyman sent the following questions to Australian Health Authorities on July 18, 2012. Among other things, she wants to know why a vaccine against human papillomavirus (HPV), which may lead to cervical cancer, is being marketed so aggressively in a country with one of the lowest rates of cervical cancer in the world. Many people in other countries have the same questions.]

By Judy Wilyman, PhD Candidate

Newsletter 4 HPV Vaccine: Answers Needed from Government Health Ministers (18.7.12)

vaccine production ignores vaccine safety?
HPV Vaccines: Many Questions

On the 12th July Australia was the first country to start a government sponsored vaccination program offering HPV vaccine to boys 12 -13 years of age. This has been implemented despite significant consumer concerns about the ingredients of this vaccine and the efficacy against any type of cancer. Below is a letter that has been sent to the TGA and other prominent public health officials in 2011 but no answers have been provided. Please investigate the ingredients of this vaccine before you give consent for your child to be innoculated. There is no active surveillance of this vaccine for causal relationships between the vaccine and adverse health events. In other words, the safety of this vaccine will never be known as nobody is studying the long-term health effects – many of which have a delayed response.

Here is the letter sent to the TGA in 2011:

In Australia, as in some other countries, the HPV vaccine – Gardasil® – is being promoted to adolescents, woman and now boys, as a vaccine to prevent cervical cancer. Government health departments are not addressing the concerns parents have about this vaccine.

There are many scientific and ethical concerns regarding the HPV vaccine and the community would like the following issues addressed:
  • This vaccine was not proven to be safe or effective against cervical cancer (CC) prior to its marketing in 2006. Phase 3 trials were not completed until 2007 1. The vaccine was trialed against pre-cancerous lesions in women 16 – 26 yrs of age in the Phase 3 trials only 2. Most pre-cancerous lesions in this age group are known to clear quickly without treatment and do not lead to cancer later in life. The relationship between pre-cancerous lesions in young adults and cervical cancer 20 to 40 years later is unknown 1. This vaccine has only been assumed to be effective against CC and now industry sponsored research is suggesting it is effective against anal cancers in men.
  • Gardasil® has 3 times the number of adverse reactions reported as all other vaccines combined 4
  • Each of the 3 injections contains 225 ug of aluminium hydroxyphosphate sulfate, an adjuvant known to be linked with autoimmune diseases, the chronic illnesses that are increasing in our population 5, 6
  • Each of the 3 injections contains sodium borate (a pesticide), which has been linked to infertility, seizures and paralysis. In 2005 the National Library of Medicine (NLM) of the National Institutes of Health declared this to be a dangerous poison and stated ‘it is no longer commonly found in medical preparations’ 7, 8. HPV vaccine was approved in 2006.
  • Each of the 3 injections also contains polysorbate 80, an emulsifier linked with anaphylaxis, convulsions, collapse, seizure (twitching) and infertility in animals 7, 8.
  • Since it was introduced, 94 deaths and 21,635 adverse reactions to Gardasil have been documented. Many have included the events listed above 9.
  • There is no systematic, long-term surveillance of adverse events to the HPV vaccine. The reporting system is a passive surveillance system. The CDC states “This (VAERS) data cannot be used to infer causal associations between vaccines and adverse events”4. If no one carefully monitors adverse reactions, there is no proof that it is safe. Yet parents are told combining vaccines is safe. This also means it will not be possible to determine whether women vaccinated against HPV will have a higher rate of infertility and autoimmune diseases in 10 – 15 years time.
  • The placebo in the clinical trials contained more aluminium adjuvant (a chemical linked with autoimmune diseases) than the vaccine itself 4. This is not a properly designed scientific study.
Why has this vaccine been marketed so aggressively to Australian women when cervical cancer is a very low risk in Australia (1.9 deaths per 100,000 women) indeed in all developed countries, and the vaccine contains chemicals linked with infertility? The other HPV vaccine (Cerverix) does not contain sodium borate or polysorbate 80, so why is it necessary to use infertility chemicals in Gardasil® which is being marketed to adolescent girls and women of all ages?
Please could you provide information and answers to the issues raised above.
Judy Wilyman
PhD  Candidate
References
1.        Vetter KM, Gellor Se, 2007, Moving Forward: human papillomavirus vaccination and the prevention of cervical cancer, Journal of Women’s Health (larchmt); Vol 16 (9): 1258 – 1268
2.        Future II Study Group, 2007, Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions, The New England Journal of Medicine, 356, 19, 1915 – 27.
3.        Australian Government, Department of Health and Ageing, 2005, “Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities, NHMRC, National Screening Program.
4.        Slade B A, Leidel L, Vellozzi C, Woo EJ, Hua Wei, Sutherland A, Izurieta H, Ball R, Miller N, Braun M, Markowitz L, Iskander J, 2009, Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine,  Journal of the American Medical Association, 302 (7): 750 – 757
5.        Villa LL, Costa R, Petta C et al, 2005, Prophylactic quadrivalent human papillomavirus (types 6,11,16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlledmulticentre phase 11 efficacy trial, Lancet Oncol 2005:6:271-8
6.        Shoenfeld Y and Agmon-Levin N, 2011, ASIA – Autoimmunity/inflammatory syndrome induced by adjuvants, Journal of Autoimmunity,36 p. 4-8.
7.        Centre for Disease Control and Protection (CDC), Vaccine Excipient and Media Summary, Part 2, excipients included in US Vaccines, by Vaccine, visited 24.5.11 www.cdc.gov/vaccines/pubs/pinkbook/downloads/spprendices/B/excipient-table-2.pdf
8.        World Association for Vaccine Education (WAVE), Vaccine Ingredients,  visited 24 May 2011 http://www.novaccine.com/
9.        S.A.N.E Vax Inc. Safe, Affordable, Necessary and Effective Vaccines,    visited 28 April 2011https://www.sanevax.org/

Related

Filed Under: Australia, Australian Concerns, Gardasil / Silgard, Vaccine Marketing Tagged With: Australia, Gardasil, HPV vaccination program, unanswered questions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

I Survived Cervarix

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

Path’s HPV Trials in India: Troubling Questions

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in

 

Loading Comments...